Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Atherosclerosis ; 185(1): 39-46, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16002075

RESUMEN

Recent studies have shown that C-reactive protein (CRP) is not just a predictor of cardiovascular events but also acts directly as a proinflammatory stimulus in vascular cells. In this report, we studied the molecular mechanisms underlying vascular cellular adhesion molecule-1 (VCAM-1) induction by CRP. CRP-induced VCAM-1 mRNA expression and this induction was inhibited by protein kinase C (PKC) inhibitors, p38 mitogen-activated protein kinase (MAPK) inhibitor, and tyrosine kinase inhibitors. In addition, parthenolide, a nuclear factor kappaB (NF-kappaB) inhibitor, abolished VCAM-1 induction. Moreover, CRP increased VCAM-1 promoter activity, indicating that CRP induces VCAM-1 mRNA expression at the transcriptional level. Mutation of NF-kappaB-binding sites resulted in a loss of induction. Finally, an electrophoretic mobility shift assay confirmed binding of the p65 subunit of NF-kappaB to kappaB-binding sites. Taken together, our findings suggest that VCAM-1 induction by CRP is mediated by PKC, p38MAPK, tyrosine kinase and the NF-kappaB-dependent signaling pathways in vascular endothelial cells.


Asunto(s)
Proteína C-Reactiva/farmacología , Células Endoteliales/metabolismo , Endotelio Vascular/metabolismo , Expresión Génica , FN-kappa B/metabolismo , ARN Mensajero/genética , Molécula 1 de Adhesión Celular Vascular/genética , Animales , Aorta/citología , Aterosclerosis/genética , Aterosclerosis/metabolismo , Aterosclerosis/patología , Northern Blotting , Bovinos , Células Cultivadas , Células Endoteliales/citología , Endotelio Vascular/citología , Humanos , Técnicas In Vitro , Mutación , FN-kappa B/genética , Transducción de Señal/fisiología , Activación Transcripcional/efectos de los fármacos , Molécula 1 de Adhesión Celular Vascular/biosíntesis
2.
Circ Res ; 95(2): 146-53, 2004 Jul 23.
Artículo en Inglés | MEDLINE | ID: mdl-15192019

RESUMEN

Endothelial PAS domain protein 1 (EPAS1) is a basic-helix-loop-helix/PAS domain transcription factor that is expressed preferentially in vascular endothelial cells. EPAS1 shares high homology with hypoxia-inducible factor-1alpha (HIF-1alpha) and is reported to transactivate vascular endothelial growth factor (VEGF), fetal liver kinase-1 (Flk-1), and Tie2 promoters. In this study, we analyzed the role of EPAS1 in the process of angiogenesis. Using microarray technology, we looked for target genes regulated by EPAS1 in vascular endothelial cells. A total of 130 genes were upregulated by EPAS1, including fms-like tyrosine kinase-1 (Flt-1). Reporter analysis using human Flt-1 promoter and gel mobility shift assays showed that the heterodimer of EPAS1 and aryl hydrocarbon receptor nuclear translocator binds directly to HIF-1-binding site upstream of Flt-1 promoter and transactivates it. Small interfering RNA targeted to EPAS1 but not HIF-1alpha attenuated desferrioxamine-induced Flt-1 mRNA expression, thus EPAS1 is thought to play an essential role in hypoxic induction of Flt-1 gene. Furthermore, using mouse wound healing models, we demonstrated that adenovirus-mediated delivery of EPAS1 gene significantly induced the expression of VEGF, Flt-1, Flk-1, and Tie2 mRNA at the wound site and promoted mature angiogenesis. The proportion of the number of mural cells in newly formed vessels was significantly higher in EPAS1-treated wound area than VEGF-treated area. In conclusion, EPAS1 promotes Flt-1 gene expression and induces mRNA expression of VEGF, Flk-1, and Tie2, leading to enhancement of mature angiogenesis in vivo. Thus, EPAS1 may contribute to the construction of mature vessels by modulating the coordinated expressions of VEGF, Flt-1, Flk-1, and Tie2.


Asunto(s)
Endotelio Vascular/metabolismo , Proteínas de la Matriz Extracelular/biosíntesis , Regulación de la Expresión Génica/fisiología , Neovascularización Fisiológica/genética , Factores de Transcripción/fisiología , Activación Transcripcional , Factor A de Crecimiento Endotelial Vascular/biosíntesis , Animales , Translocador Nuclear del Receptor de Aril Hidrocarburo , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico , Sitios de Unión , Bovinos , Células Cultivadas/efectos de los fármacos , Células Cultivadas/metabolismo , Quimiotaxis/efectos de los fármacos , Proteínas de Unión al ADN/metabolismo , Proteínas de Unión al ADN/fisiología , Deferoxamina/farmacología , Dimerización , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Proteínas de la Matriz Extracelular/genética , Perfilación de la Expresión Génica , Regulación de la Expresión Génica/efectos de los fármacos , Terapia Genética , Humanos , Factor 1 Inducible por Hipoxia , Subunidad alfa del Factor 1 Inducible por Hipoxia , Masculino , Ratones , Ratones Endogámicos BALB C , Cadenas Pesadas de Miosina , Miosina Tipo IIB no Muscular , Proteínas Nucleares/fisiología , Análisis de Secuencia por Matrices de Oligonucleótidos , Regiones Promotoras Genéticas , ARN Mensajero/biosíntesis , ARN Interferente Pequeño/farmacología , Receptor TIE-2/biosíntesis , Receptor TIE-2/genética , Receptores de Hidrocarburo de Aril/metabolismo , Proteínas Recombinantes de Fusión/fisiología , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Factor A de Crecimiento Endotelial Vascular/genética , Factor A de Crecimiento Endotelial Vascular/farmacología , Receptor 1 de Factores de Crecimiento Endotelial Vascular , Receptor 2 de Factores de Crecimiento Endotelial Vascular/biosíntesis , Receptor 2 de Factores de Crecimiento Endotelial Vascular/genética , Cicatrización de Heridas/genética
3.
Atherosclerosis ; 169(1): 105-12, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12860256

RESUMEN

Recently, variants in ATP-binding cassette transporter A1 (ABCA1) were demonstrated to be associated with increased level of high density lipoprotein cholesterol (HDL-C) and decreased risk of coronary artery disease (CAD) in Caucasians. However, this is not universally applicable due to the ethnic or environmental differences. In this context, to clarify the effect of ABCA1 in Japanese, we evaluated the phenotypic effects of I/M 823 and R/K 219 variants on the plasma level of HDL-C in 410 patients recruited in our hospital. Subjects with M 823 allele had significantly higher level of HDL-C than those without M823 allele (49.0+/-15.1 vs. 44.9+/-11.5 mg/dl, respectively, P<0.05). This statistical significance did not change even after multiple regression analysis. In contrast, there was no difference in HDL-C level among the genotypes in R/K 219 polymorphism. Further, in our study population an inverse relationship was shown to exist between HDL-C level and incidence of CAD. However, no positive association was observed between those variants and susceptibility to CAD. In this study, we provide evidence that I/M 823 variant, not R/K 219 variant, in ABCA1 is one of the determinants of HDL-C level, suggesting the importance of this gene on lipid metabolism in Japanese.


Asunto(s)
Transportadoras de Casetes de Unión a ATP/genética , HDL-Colesterol/sangre , Polimorfismo Genético , Transportador 1 de Casete de Unión a ATP , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Enfermedad Coronaria/etnología , Enfermedad Coronaria/genética , Femenino , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Hiperlipidemias/sangre , Hiperlipidemias/genética , Japón , Desequilibrio de Ligamiento , Masculino , Persona de Mediana Edad
4.
Int J Cardiol ; 92(2-3): 181-6, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14659851

RESUMEN

Matrix metalloproteinases (MMPs) are involved in plaque rupture, which is the main pathological cause of myocardial infarction (MI). Recently, several genetic studies have demonstrated that MMP-1 1G/2G polymorphism and MMP-3 5A/6A polymorphism modify each transcriptional activity in allele specific manners. Within this context, we conducted case-control studies to examine whether these genetic polymorphisms are associated with susceptibility to MI. Two groups comprising patients with MI (group-1 164 patients, group-2 302 patients) were compared with control group comprising 335 patients without cardiovascular diseases. The MMP-3 5A allele was more frequent in patients with MI than in the control subjects (P=0.018 MI group-1, P=0.0059 MI group-2), whereas there was no disease association for MMP-1 genotypes. Logistic regression analyses revealed that MMP-3 5A/6A polymorphism was associated with susceptibility to MI [odds ratio(OR) (95% confidential interval) 1.67 (1.02-2.74); P=0.042, MI group-1; 1.61 (1.12-2.23); P=0.0095, MI group-2]. Other important findings were that there was strong linkage disequilibrium between these polymorphisms, which are located closely on chromosome 11q.22, and that the 5A-1G haplotype was a genetic risk factor for MI (OR 1.97 P=0.0082, MI group-1 OR 1.51 P=0.017, MI group-2). Taken together, the present findings suggest that genetic variations in these MMP genes and especially their haplotype may be useful genetic markers for determining susceptibility to MI in Japanese.


Asunto(s)
Pueblo Asiatico , Metaloproteinasa 1 de la Matriz/genética , Metaloproteinasa 3 de la Matriz/genética , Infarto del Miocardio/etnología , Anciano , Estudios de Casos y Controles , Cromosomas Humanos Par 11/genética , Femenino , Predisposición Genética a la Enfermedad , Variación Genética , Humanos , Japón/epidemiología , Desequilibrio de Ligamiento , Modelos Logísticos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/genética , Polimorfismo Genético , Regiones Promotoras Genéticas
5.
Circ J ; 69(8): 994-5, 2005 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16041174

RESUMEN

A 60 year-old male was referred for treatment of a cardiac myxoma in the right atrium. He had a past history of left atrial cardiac myxoma at age 49 and pituitary microadenoma related to acromegaly at age 55. He did not have a family history of cardiac neoplasm or endocrinopathy. The intracardiac tumor was resected and its pathology was compatible with myxoma. A diagnosis of Carney complex (CNC) was made because the diagnostic criteria of this neoplastic syndrome were satisfied by the presence of recurrent cardiac myxoma, endocrine tumor and spotty skin pigmentation. In genetic analysis novel frame shift mutation was detected in exon 2 in a heterozygous fashion in the causative gene of CNC, protein kinase A regulatory subunit 1 alpha (PRKAR1A). This genetic mutation is thought to cause haplo-insufficiency of PRKAR1A resulting in tumorigenesis. Although it is the most common, usually benign, cardiac tumor, myxoma can cause a critical clinical situation and thus detecting the PRKAR1A mutation can assist with prognosis.


Asunto(s)
Neoplasias de las Glándulas Endocrinas/genética , Neoplasias Cardíacas/genética , Mutación , Mixoma/genética , Proteínas/genética , Acromegalia/complicaciones , Acromegalia/diagnóstico , Acromegalia/genética , Subunidad RIalfa de la Proteína Quinasa Dependiente de AMP Cíclico , Proteínas Quinasas Dependientes de AMP Cíclico , Neoplasias de las Glándulas Endocrinas/complicaciones , Neoplasias de las Glándulas Endocrinas/diagnóstico , Neoplasias Cardíacas/complicaciones , Neoplasias Cardíacas/diagnóstico , Humanos , Masculino , Persona de Mediana Edad , Mixoma/complicaciones , Mixoma/diagnóstico
6.
Biochem Biophys Res Commun ; 314(2): 415-9, 2004 Feb 06.
Artículo en Inglés | MEDLINE | ID: mdl-14733921

RESUMEN

Resistin is an adipocytokine which plays a role in the development of insulin resistance. In this study, we investigated the direct effect of resistin on vascular endothelial cells. Resistin induced the expression of adhesion molecules such as VCAM-1 and ICAM-1, and long pentraxin 3, a marker of inflammation. The induction of VCAM-1 by resistin was inhibited partially by pitavastatin. Moreover, the induction of VCAM-1 and ICAM-1 by resistin was inhibited by adiponectin, an adipocytokine that improves insulin resistance. Taken together, these results suggest that the balance in the concentrations of adipocytokines such as resistin and adiponectin determines the inflammation status of vasculature, and in turn the progress of atherosclerosis.


Asunto(s)
Adipocitos/metabolismo , Citocinas/metabolismo , Células Endoteliales/metabolismo , Hormonas Ectópicas/fisiología , Péptidos y Proteínas de Señalización Intercelular , Proteínas/fisiología , Adiponectina , Animales , Arteriosclerosis/patología , Northern Blotting , Western Blotting , Proteína C-Reactiva/metabolismo , Comunicación Celular , Células Cultivadas , Relación Dosis-Respuesta a Droga , Genes Reporteros , Humanos , Resistencia a la Insulina , Molécula 1 de Adhesión Intercelular/metabolismo , Ratones , FN-kappa B/metabolismo , Proteínas/metabolismo , Quinolinas/metabolismo , ARN Mensajero/metabolismo , Resistina , Componente Amiloide P Sérico/metabolismo , Factores de Tiempo , Transfección , Molécula 1 de Adhesión Celular Vascular/metabolismo
7.
Jpn Heart J ; 45(2): 315-24, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15090708

RESUMEN

Nowadays, evidence-based medicine has entered the mainstream of clinical judgement and the human genome has been completely decoded. Even the concept of individually designed medicine, that is, tailor-made medicine, is now being discussed. Due to their complexity, however, management methods for clinical information have yet to be established. We have conducted a study on a universal technique which enables one to select or produce by employing information processing technology clinical findings from various clinical information generated in vast quantity in day-to-day clinical practice, and to share such information and/or the results of analysis between two or more institutions. In this study, clinically useful findings have been successfully obtained by systematizing actual clinical information and genomic information obtained by an appropriate collecting and management method of information with due consideration to ethical issues. We report here these medical achievements as well as technological ones which will play a role in propagating such medical achievements.


Asunto(s)
Sistemas de Apoyo a Decisiones Clínicas , Sistemas de Información , Sistemas de Información Administrativa , Inteligencia Artificial , Enfermedad Coronaria/diagnóstico , Bases de Datos como Asunto , Técnicas de Apoyo para la Decisión , Medicina Basada en la Evidencia , Genoma Humano , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA